The role of asunercept as a selective CD95L inhibitor in cutaneous melanoma: Rationale and results from an enhanced TiRP model

The role of asunercept as a selective CD95L inhibitor in cutaneous melanoma: Rationale and results from an enhanced TiRP model

Bibliografische gegevens
Hoofdauteurs:	Krendyukov, A, Kneisel, N, Zhu, J, Merz, C, Richards, D, Gieffers, C, Van Den Eynde, B
Andere auteurs:	Mitchell, T
Formaat:	Conference item
Taal:	English
Gepubliceerd in:	Elsevier 2020

Gelijkaardige items

Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies
door: Krendyukov A, et al.
Gepubliceerd in: (2019-09-01)

CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence
door: Richards DM, et al.
Gepubliceerd in: (2021-03-01)

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients
door: Nina Hanke, et al.
Gepubliceerd in: (2019-04-01)

Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trialResearch in context
door: Maria Pilar Ruiz Seco, et al.
Gepubliceerd in: (2024-11-01)

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence
door: Charlotte Lemech, et al.
Gepubliceerd in: (2012-03-01)

The abscopal effect of anti-CD95 and radiotherapy in melanoma
door: Jixiang Xu, et al.
Gepubliceerd in: (2023-05-01)

Concepts for agonistic targeting of CD40 in immuno-oncology
door: David M. Richards, et al.
Gepubliceerd in: (2020-02-01)

Death Induced by CD95 or CD95 Ligand Elimination
door: Abbas Hadji, et al.
Gepubliceerd in: (2014-04-01)

Genetics of Uveal Melanoma and Cutaneous Melanoma: Two of a Kind?
door: Thomas van den Bosch, et al.
Gepubliceerd in: (2010-01-01)

Epidemiología del melanoma cutáneo Epidemiology of cutaneous melanoma
door: R M C Leitner
Gepubliceerd in: (2006-06-01)

Dormancy of cutaneous melanoma
door: Kathrin Singvogel, et al.
Gepubliceerd in: (2024-02-01)

Mandibular metastasis of cutaneous melanoma
door: Josi Amadeu, et al.
Gepubliceerd in: (2016-09-01)

Metastatic Cutaneous Melanoma of the Gallbladder
door: Dhruvan Patel, et al.
Gepubliceerd in: (2017-01-01)

Cutaneous melanoma in older patients
door: Alessandra Buja, et al.
Gepubliceerd in: (2024-03-01)

Cutaneous horn malignant melanoma
door: Haruto Nishida, et al.
Gepubliceerd in: (2013-12-01)

Metabolic Traits in Cutaneous Melanoma
door: Monica Neagu, et al.
Gepubliceerd in: (2020-05-01)

Amelanotic metastatic cutaneous melanoma
door: Marcela Sena Teixeira Mendes, et al.
Gepubliceerd in: (2013-12-01)

Malignant melanoma - cutaneous metastases
door: Padmavathy L, et al.
Gepubliceerd in: (2008-01-01)

Cutavirus in Cutaneous Malignant Melanoma
door: Sarah Mollerup, et al.
Gepubliceerd in: (2017-02-01)

Melanoma inhibitory activity in Brazilian patients with cutaneous melanoma
door: Macanori Odashiro, et al.
Gepubliceerd in: (2015-06-01)

Evaluation of outpatient discharge in patients with cutaneous melanoma
door: Nurimar C. Fernandes, et al.

Accumulation of CD103+ CD8+ T cells in a cutaneous melanoma micrometastasis
door: Katharina Hochheiser, et al.
Gepubliceerd in: (2019-01-01)

Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy
door: Sandra Martinez-Morilla, et al.
Gepubliceerd in: (2023-12-01)

Solar Lentigines are Associated with Better Outcome in Cutaneous Melanoma
door: Vivien Marasigan, et al.
Gepubliceerd in: (2019-09-01)

The Dark Side of Melanin Secretion in Cutaneous Melanoma Aggressiveness
door: Luís C. Cabaço, et al.
Gepubliceerd in: (2022-05-01)

The dual role of the CD95 and CD95L signaling pathway in glioblastoma
door: Yanrui Zhang, et al.
Gepubliceerd in: (2022-11-01)

Modulation of the CD95-induced apoptosis: the role of CD95 N-glycosylation.
door: Olga M Shatnyeva, et al.
Gepubliceerd in: (2011-01-01)

Management of metastatic cutaneous melanoma: updates in clinical practice
door: Gustavo Schvartsman, et al.
Gepubliceerd in: (2019-05-01)

Prognostic value of B cells in cutaneous melanoma
door: Sara R. Selitsky, et al.
Gepubliceerd in: (2019-05-01)

Subversion of Ras Small GTPases in Cutaneous Melanoma Aggressiveness
door: Cheila Brito, et al.
Gepubliceerd in: (2020-09-01)

Targeting the Hippo Pathway in Cutaneous Melanoma
door: Urszula Kazimierczak, et al.
Gepubliceerd in: (2024-06-01)

Unaddressed Challenges in the Treatment of Cutaneous Melanoma?
door: Alessia Villani, et al.
Gepubliceerd in: (2024-05-01)

Cutaneous melanoma: new advances in treatment
door: Michele Ceolin Foletto, et al.
Gepubliceerd in: (2014-04-01)

Hidden Sentinel Node in Cutaneous Melanoma
door: Francesco Segreto, et al.
Gepubliceerd in: (2013-09-01)

Characteristics and Treatment of Cutaneous Melanoma of the Foot
door: Kyung Wook Nam, et al.
Gepubliceerd in: (2016-01-01)

Pre-clinical modeling of cutaneous melanoma
door: Vito W. Rebecca, et al.
Gepubliceerd in: (2020-06-01)

Multiple cutaneous metastases of amelanotic melanoma
door: Priscila Vinhal Grupioni, et al.
Gepubliceerd in: (2018-03-01)

Cutaneous melanoma: some current considerations
door: María Cristina Infante Carbonell, et al.
Gepubliceerd in: (2019-02-01)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
door: Diogo Garcia, et al.
Gepubliceerd in: (2021-06-01)

Correction: CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells
door: Moritz Drachsler, et al.
Gepubliceerd in: (2020-07-01)